title: Preparation, biodistribution and dosimetry of copper-64-labeled anti-colorectal carcinoma monoclonal antibody fragments 1A3-F(ab')2.
abstract: Antibody fragments labeled with a radiometal using bifunctional chelates generally undergo renal clearance followed by trapping of the metabolites, leading to high radiation doses to the kidneys. Copper-64-labeled BAT-2IT-1A3-F(ab')2 was recently reported to accumulate in colorectal tumors in an animal model, however, kidney uptake was also high. In this study, the preparation of 64Cu-BAT-2IT-1A3-F(ab')2 was optimized to reduce the renal uptake.
  
  
  METHODS
  The bifunctional chelate 6-bromoacetamidobenzyl-1,4,8,11-tetraazacyclotetradecane-N,N ',N",N'"-tetraacetic acid (BAT) was conjugated to 1A3-F(ab')2 using the linking agent 2-iminothiolane (2IT). The conjugation reaction produced 20% of a lower molecular weight (molecular wieght) impurity found to be TETA-1A3-Fab'. The conjugation procedure was optimized to include FPLC purification of the BAT-2IT-1A3-F(ab')2 from TETA-1A3-Fab' after conjugation prior to labeling with 64Cu. The biodistribution of 64Cu-labeled FPLC-purified and unpurified conjugates was determined in normal Sprague-Dawley rats and tumor bearing Golden Syrian hamsters. Human absorbed doses were calculated from rat biodistribution data and PET imaging of a baboon.
  
  
  RESULTS
  Upon FPLC purification of the BAT-2IT-1A3-F(ab')2, the immunoreactivity of 64Cu-labeled 1A3-F(ab')2 was significantly improved over that of non-FPLC-purified 64Cu-BAT-2IT-1A3-F(ab')2, and the kidney uptake was decreased in normal rats. The biodistribution in hamsters showed some improvement in both tumor uptake and kidney clearance with FPLC-purified 64Cu-BAT-2IT-1A3-F(ab')2.
  
  
  CONCLUSIONS
  The improved dosimetry of 64Cu-labeled FPLC purified BAT-2IT-1A3-F(ab')2 should more readily allow this agent to be investigated clinically to image colorectal cancer using PET.
authors.affiliation: Mallinckrodt Institute of Radiology, St Louis, MO 63110, USA.
authors.forename: C J
authors.initials: CJ
authors.lastname: Anderson
authors.forename: S W
authors.initials: SW
authors.lastname: Schwarz
authors.forename: J M
authors.initials: JM
authors.lastname: Connett
authors.forename: P D
authors.initials: PD
authors.lastname: Cutler
authors.forename: L W
authors.initials: LW
authors.lastname: Guo
authors.forename: C J
authors.initials: CJ
authors.lastname: Germain
authors.forename: G W
authors.initials: GW
authors.lastname: Philpott
authors.forename: K R
authors.initials: KR
authors.lastname: Zinn
authors.forename: D P
authors.initials: DP
authors.lastname: Greiner
authors.forename: C F
authors.initials: CF
authors.lastname: Meares
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging / Q000276:immunology*; D003301:Copper Radioisotopes / Q000493:pharmacokinetics; D006224:Cricetinae; D007128:Immunoglobulin Fragments; D008647:Mesocricetus; D010215:Papio; D011877:Radionuclide Imaging; D051381:Rats; D017207:Rats, Sprague-Dawley; D014018:Tissue Distribution
chemical_list: D000911:Antibodies, Monoclonal; D003301:Copper Radioisotopes; D007128:Immunoglobulin Fragments